跳至主要内容
临床试验/EUCTR2015-002397-21-AT
EUCTR2015-002397-21-AT进行中(未招募)1 期

FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIL - ENALONG

Ethicare GmbH0 个研究点目标入组 85 人开始时间: 2015年10月19日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Ethicare GmbH
入组人数
85

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients from the WP08 and WP09 trials who have been treated with enalapril Orodispersible Minitablets and are still under ODMT treatment.
  • Patients from the WP08 and WP09 trials who have been treated with at least 3 doses of enalapril Orodispersible Minitablets and are not anymore under ODMT treatment.
  • Patient and/or parent(s)/legal guardian provided written informed consent for participation in this long term follow-up study.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 85
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients who have been enrolled and treated in the WP08 or WP09 trials have fulfilled the respective in- and exclusion criteria of those protocols. As it is the aim of this Follow-up Study to observe the safety of all patients exposed to enalapril ODMT treatment, no additional exclusion criteria are defined in this protocol.

研究者

发起方
Ethicare GmbH

相似试验

进行中(未招募)
1 期
FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIHeart Failure due to Dilated Cardiomyopathy and Congenital Heart DiseaseMedDRA version: 18.1Level: LLTClassification code 10010495Term: Congenital heart disease NOSSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10056419Term: Dilated cardiomyopathySystem Organ Class: 100000004849
EUCTR2015-002397-21-HUEthicare GmbH100
进行中(未招募)
不适用
FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRI
EUCTR2015-002397-21-NLEthicare GmbH100
进行中(未招募)
1 期
FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIHeart Failure due to Dilated Cardiomyopathy and Congenital Heart DiseaseMedDRA version: 20.0Level: LLTClassification code 10010495Term: Congenital heart disease NOSSystem Organ Class: 100000011531MedDRA version: 20.0Level: LLTClassification code 10056419Term: Dilated cardiomyopathySystem Organ Class: 100000011725
EUCTR2015-002397-21-DEEthicare GmbH85
进行中(未招募)
不适用
FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRI
EUCTR2015-002397-21-GBEthicare GmbH100
已完成
2 期
Follow-up Safety Trial in children with chronic heart failure therapy receiving Orodispersible Minitablets of Enalapril (WP10 Trial).hartaandoeningen, myocardaandoeningen10010394Dilated CardiomyopathyCongenital Heart Disease
NL-OMON46324Ethicare GmbH11